Format

Send to

Choose Destination
Curr Oncol Rep. 2018 Jun 30;20(9):66. doi: 10.1007/s11912-018-0711-0.

Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.

Author information

1
Department of Therapeutic Radiology, Yale School of Medicine, HRT 138, 333 Cedar St, New Haven, CT, 06520, USA.
2
Department of Therapeutic Radiology, Yale School of Medicine, HRT 138, 333 Cedar St, New Haven, CT, 06520, USA. james.b.yu@yale.edu.
3
Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT, USA. james.b.yu@yale.edu.

Abstract

PURPOSE OF REVIEW:

Here, we will review and summarize the current status and emerging data supporting the use of trimodality therapy as an alternative to cystectomy for patients with muscle-invasive bladder cancer.

RECENT FINDINGS:

There are no randomized-controlled data comparing radical cystectomy with bladder preserving trimodality therapy available for comparison. However, observational data suggests acceptable bladder preservation and functional outcomes in patients receiving bladder preserving trimodality therapy as well as similar oncologic outcomes in select patients compared to radical cystectomy. Future trials are focusing on new techniques and novel therapeutics in patients with bladder cancer. Bladder preserving trimodality therapy results in satisfactory quality of life and comparable disease outcomes for select patients with muscle-invasive urothelial carcinoma of the bladder compared to cystectomy.

KEYWORDS:

Bladder cancer; Bladder preservation; Muscle-invasive; Trimodality therapy

PMID:
29959582
DOI:
10.1007/s11912-018-0711-0

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center